|
Nivolumab Injectable Product Clinical Trials
2 actively recruiting trials across 2 locations
▼ -1 trial since June 2026
Also known as: OPDIVO, immune checkpoint inhibitor
Pipeline
Phase 1: 1Phase 2: 1
Top Sponsors
- Teclison Ltd.1
- Baylor College of Medicine1
Indications
- Cancer2
- Liver Disease1
- Undifferentiated Sarcoma1
- Synovial Sarcoma1
- HER-2 Protein Overexpression1
Orange, California1 trial
Combination of TATE and PD-1 Inhibitor in Liver Cancer
University of California, Irvine
Phase 2
Houston, Texas1 trial
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Texas Children's Hospital
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.